Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Dennis A. Ausiello sold 20,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $130.00, for a total value of $2,600,000.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $2,600,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $132.36 on Monday. The company has a current ratio of 8.84, a quick ratio of 8.84 and a debt-to-equity ratio of 0.13. Alnylam Pharmaceuticals, Inc. has a 52-week low of $31.42 and a 52-week high of $147.63.

ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Director Sells $2,600,000.00 in Stock” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-director-sells-2600000-00-in-stock/1681913.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 36 shares during the last quarter. State of Wisconsin Investment Board grew its stake in Alnylam Pharmaceuticals by 0.7% in the second quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares in the last quarter. Prudential Financial Inc. grew its stake in Alnylam Pharmaceuticals by 4.8% in the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 200 shares in the last quarter. Finally, Utah Retirement Systems boosted its stake in Alnylam Pharmaceuticals by 1.5% in the second quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after acquiring an additional 200 shares during the period. 94.20% of the stock is currently owned by institutional investors and hedge funds.

ALNY has been the subject of a number of recent analyst reports. B. Riley started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They issued a “buy” rating and a $240.00 target price for the company. Credit Suisse Group boosted their price target on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a research note on Friday. Stifel Nicolaus reiterated a “buy” rating and set a $56.00 price objective (up from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. FBR & Co assumed coverage on Alnylam Pharmaceuticals in a research note on Monday, October 30th. They set a “buy” rating and a $150.00 price objective for the company. Finally, Chardan Capital restated a “buy” rating and issued a $124.00 price target (down from $131.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $109.66.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.